| 000 | 01164 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250512093229.0 | ||
| 264 | 0 | _c19700205 | |
| 008 | 197002s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(69)90940-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWalshe, J M | |
| 245 | 0 | 0 |
_aManagement of penicillamine nephropathy in Wilson's disease: a new chelating agent. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cDec 1969 |
||
| 300 |
_a1401-2 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aChelating Agents _xtherapeutic use |
| 650 | 0 | 4 | _aChlorides |
| 650 | 0 | 4 |
_aCopper _xmetabolism |
| 650 | 0 | 4 |
_aEthylenediamines _xtherapeutic use |
| 650 | 0 | 4 |
_aHepatolenticular Degeneration _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNephrotic Syndrome _xchemically induced |
| 650 | 0 | 4 | _aNeurologic Manifestations |
| 650 | 0 | 4 |
_aPenicillamine _xadverse effects |
| 773 | 0 |
_tLancet (London, England) _gvol. 2 _gno. 7635 _gp. 1401-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(69)90940-4 _zAvailable from publisher's website |
| 999 |
_c4193661 _d4193661 |
||